<DOC>
	<DOCNO>NCT01781390</DOCNO>
	<brief_summary>This double blind , randomize , placebo control study enroll 225 subject de novo anterior myocardial infarction due lesion leave anterior descend coronary artery undergo PCI . Eligible subject enrol undergo revascularization culprit LAD follow intracoronary ( IC ) delivery assign treatment , infuse stented culprit artery . The study determine safety feasibility IC infusion investigational MPCs patient population .</brief_summary>
	<brief_title>Safety Study Allogeneic Mesenchymal Precursor Cell Infusion MyoCardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Key Clinical symptom consistent AMI ( pain , etc . ) maximum 12 hour onset symptom percutaneous coronary intervention ( PCI ) De Novo anterior Acute Myocardial Infarct ( AMI ) Successful revascularization culprit lesion Key Prior AMI , know cardiomyopathy , hospital admission heart failure ( HF ) Significant valvular disease Need interventional surgical procedure treat heart disease ( plan schedule ) Cardiogenic shock hemodynamic instability within 24 hour randomization Prior PCI LAD Pacemaker , ICD ( Implantable Cardioverter Defibrillator ) , contraindication cardiac MRI Prior current participation stem cell study investigational trial past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Acute Myocardial Infarction</keyword>
	<keyword>STEMI</keyword>
	<keyword>Heart Attack</keyword>
	<keyword>AMI</keyword>
	<keyword>Stem Cells</keyword>
</DOC>